Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

Add PRPO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/15/2018 9:44:59 AM - Followers: 67 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TBIO News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/19/2017 06:04:50 AM
TBIO News: Statement of Changes in Beneficial Ownership (4) 09/15/2017 04:31:57 PM
TBIO News: Current Report Filing (8-k) 09/08/2017 04:35:38 PM
TBIO News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/05/2017 05:27:33 PM
TBIO News: Current Report Filing (8-k) 08/31/2017 04:32:56 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1666   PRPO: Precipio Launches Unique Lung Cancer Monitoring Test aries4747 02/15/18 09:44:59 AM
#1665   PRPO: Precipio Issues $1.9M in Shares to Cancel Debt aries4747 02/15/18 09:43:20 AM
#1664   Do you think they will do another RS Billem 02/14/18 10:09:54 AM
#1663   Yes, I did, and may buy some more tomorrow. laser777 02/11/18 12:12:02 PM
#1662   did anyone else buy? my name is 02/10/18 10:49:49 PM
#1661   Precipio Announces Q4 2017 Revenue at 350% of laser777 02/09/18 10:07:27 AM
#1660   Precipio Enters Japanese Liquid Biopsy Market with First laser777 02/06/18 03:29:22 PM
#1659   Expecting good things from this opportunity. Appears that PennyStockTrader2 01/26/18 09:51:03 PM
#1658   just looking for anyone else that agrees from my name is 01/25/18 10:33:12 PM
#1657   Wow, then to the moon alice, is not laser777 01/25/18 09:53:02 PM
#1656   i only look at candles please leave the my name is 01/25/18 08:50:18 PM
#1655   Then, if you read the highlighted portion of laser777 01/24/18 09:13:36 PM
#1654   The company seems to finally on a good laser777 01/24/18 09:01:26 PM
#1653   this thing looks like it could go to my name is 01/20/18 02:25:54 PM
#1652   PRPO (1.2238): Yale Study Demonstrates Four-Fold Superiority of aries4747 01/10/18 10:32:07 AM
#1651   NEWS... laser777 12/20/17 09:29:28 AM
#1650   Built up a decent position averaging in @$1.15 PennyStockTrader2 12/19/17 09:44:41 AM
#1649   Check out the other older AccessWire news from aries4747 12/14/17 02:51:15 PM
#1648   Thanks. I wasn't saying the news was irrelevant. I laser777 12/14/17 02:45:46 PM
#1647   That news release never got much attention because aries4747 12/14/17 02:08:09 PM
#1646   PRPO:Precipio Files a Patent Application for IV-Cell, its aries4747 12/14/17 01:56:32 PM
#1645   news is news 02opida 12/08/17 03:35:37 PM
#1644   So, this is old news? laser777 12/08/17 02:14:43 PM
#1643 02opida 12/08/17 11:13:26 AM
#1642   Is this new news, and if so, do laser777 12/08/17 10:58:07 AM
#1641   Receives New $750,000 Project from Existing Pharmaceutical Client 02opida 12/08/17 09:49:10 AM
#1640   Company Update on Monday, November 20, 2017 califax 11/17/17 11:44:40 AM
#1639   PRPO (1.42): Interesting volume coming in. aries4747 11/10/17 01:30:49 PM
#1638   PRPO (1.76): Precipio Announces Completion of Substantial Balance aries4747 11/01/17 03:05:13 PM
#1637   13D/A 14% shanak10 10/17/17 03:25:48 PM
#1636   Precipio's ICE COLD-PCR(TM) Technology Selected by the University laser777 10/17/17 09:38:01 AM
#1635   Precipio Launches Its First Re-Designed ICE-COLD PCR(TM) Targeted laser777 10/12/17 09:26:17 AM
#1634   PRPO (1.88): Precipio Re-Launches All CLIA Lab and aries4747 10/11/17 12:26:16 AM
#1633   PRPO (2.25): Up 25% on nice volume. aries4747 09/28/17 11:24:32 AM
#1632   Looking back, they didn't file an 8-K for aries4747 09/26/17 11:39:49 AM
#1631   GM. Surprised they didn't Pr it. Material event. mgland 09/26/17 09:56:41 AM
#1630   PRPO 9/12 conference call link aries4747 09/25/17 10:14:46 AM
#1629   Nice work, and a very nice find, thank you! laser777 09/22/17 08:36:03 AM
#1628   PRPO (1.84): EU officially grants patent. aries4747 09/21/17 09:46:50 PM
#1627   PRPO: Precipio Provides Shareholder Update Letter aries4747 09/08/17 01:07:15 AM
#1626   Ringing the bell? richrichrich 09/03/17 10:06:12 PM
#1625   PRPO (2.28): Precipio, Inc. Announces Closing of Public aries4747 09/01/17 09:13:03 AM
#1624   Biotechs so risky. This stock is hilarious. Surfacetite 08/24/17 12:30:38 AM
#1623   it`s toast !! califax 08/23/17 09:15:37 AM
#1622   VERY interesting "liquid biopsy" article published today. aries4747 08/17/17 05:00:32 PM
#1621   PRPO 10Q due early next week. aries4747 08/17/17 03:23:29 PM
#1620   PRPO Chart for traders conix 08/01/17 11:14:27 AM
#1619   Proposed Public Offering bradlee 08/01/17 10:42:34 AM
#1618   PRPO will ring the opening bell at NASDAQ bradlee 07/12/17 07:50:59 AM
#1617   Precipio 02opida 07/11/17 03:57:06 PM